182 related articles for article (PubMed ID: 7896180)
1. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
[TBL] [Abstract][Full Text] [Related]
2. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de Nictolis M; Muzzioli M; Fabris N; Romanini C; Biagini G
Gynecol Oncol; 1995 Jul; 58(1):28-33. PubMed ID: 7789886
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining.
Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G
Gynecol Oncol; 1999 Jun; 73(3):396-401. PubMed ID: 10366466
[TBL] [Abstract][Full Text] [Related]
4. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract.
Chowdhury GM; Kojima K; Kanayama H; Tsuji M; Kurokawa Y; Kagawa S
Cancer; 1996 Aug; 78(4):827-33. PubMed ID: 8756378
[TBL] [Abstract][Full Text] [Related]
5. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
6. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant role of MIB1 index in differentiating serous ovarian tumors-preliminary report.
Frigerio L; Agnello A; Sassi I; Mangili F; Taccagni G; Mariani A; Ferrari A
Anticancer Res; 1997; 17(2B):1287-92. PubMed ID: 9137487
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
9. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
11. Quality control considerations for Ki-67 detection and quantitation in paraffin-embedded tissue.
Hendricks JB; Wilkinson EJ
J Cell Biochem Suppl; 1994; 19():105-10. PubMed ID: 7823581
[TBL] [Abstract][Full Text] [Related]
12. Mib-1 evaluated proliferative activity in ovarian cancer with respect to prognostic significance.
Marx D; Meden H; Brune T; Kron M; Korabiowska M; Kuhn W; Schauer A
Anticancer Res; 1997; 17(1B):775-80. PubMed ID: 9066619
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
Kritpracha K; Hanprasertpong J; Chandeying V; Dechsukhum C; Geater A
J Obstet Gynaecol Res; 2005 Jun; 31(3):268-76. PubMed ID: 15916666
[TBL] [Abstract][Full Text] [Related]
14. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors.
Garzetti GG; Ciavattini A; Lucarini G; Pugnaloni A; De Nictolis M; Amati S; Romanini C; Biagini G
Cancer; 1999 May; 85(10):2219-25. PubMed ID: 10326701
[TBL] [Abstract][Full Text] [Related]
17. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
18. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
Salvesen HB; Iversen OE; Akslen LA
Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
[TBL] [Abstract][Full Text] [Related]
19. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
[TBL] [Abstract][Full Text] [Related]
20. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
